Abstract Prophylactic eradication of central nervous system (CNS) leukaemia is the current standard of care in treating childhood acute lymphoblastic leukaemia (ALL). This is conventionally achieved through regular lumbar punctures with intrathecal injections of methotrexate into the cerebrospinal fluid (CSF). Ommaya reservoirs are subcutaneous implantable devices that provide a secure route of drug delivery into the CSF via an intraventricular catheter. They are an important alternative in cases where intrathecal injection via lumbar puncture is difficult. Among UK Paediatric Principal Treatment Centres for ALL we found considerable variation in methotrexate dosing when using an Ommaya reservoir. We review the current safety and theoretical considerations when using Ommaya reservoirs and evidence for methotrexate dose adjustments via this route. We conclude by summarising the pragmatic consensus decision to use 50% of the conventional intrathecal dose of methotrexate when it is administered via Ommaya reservoir in front-line ALL therapy.
Introduction
The central nervous system (CNS) remains an important sanctuary site for childhood acute lymphoblastic leukaemia (ALL) [1] . Although overt CNS infiltration is only seen in 2-5% of children at initial diagnosis, approximately 40% of relapses involve the CNS [2, 3] . Without CNS-directed chemotherapy, up to 75% of patients will relapse within the CNS [4] , and yet no reliable predictors of relapse risk have been identified. Both clinical observations and experimental models suggest that subclinical CNS infiltration is likely to be present in the majority of patients at initial diagnosis. For this reason, all patients currently receive 'prophylactic' CNS treatment regardless of the presence of detectable leukaemia in samples of cerebrospinal fluid (CSF). This treatment is potentially toxic to the developing brain and can produce neurocognitive impairment [5] . In addition, relapse within the CNS can be refractory to conventional chemotherapy and/or bone marrow (BM) transplantation [1] . CNS control is now often achieved using intrathecal chemotherapy (delivered directly into the circulating CSF via lumbar puncture) [4, 6] and systemic drugs with good CNS penetration, instead of cranial irradiation. This change followed observation of the long-term adverse effects of cranial irradiation, such as development of secondary cancers, endocrinopathies and neurocognitive impairment [1] . Methotrexate is the commonest intrathecal agent used in ALL, either alone or in combination with cytarabine and hydrocortisone (so-called triple therapy). Several studies have demonstrated comparable efficacy and similar rates of CNS relapse using intrathecal methotrexate or triple therapy compared with results using cranio-spinal irradiation [7] [8] [9] . Consequently, many trial groups now use intensive intrathecal chemotherapy as the standard of care for prophylaxis and treatment of CNS leukaemia, whilst others reserve cranial irradiation for those at highest risk of CNS relapse.
Clinically, there are two methods of delivering CNSdirected chemotherapy. Conventionally, intrathecal lumbar puncture is used to administer chemotherapy into the lumbosacral CSF space. Alternatively, chemotherapy can be administered via an implantable Ommaya reservoir, a small device comprising a capsule, situated between the cranium and overlying skin connected to a catheter communicating directly with one of the lateral ventricles [10] . The Ommaya reservoir allows for repeated CSF sampling and for chemotherapy to be delivered directly into the cerebral ventricles, rather than relying on CSF flow from the lumbar to the cranial regions. While lumbar punctures are the standard route of delivery for intrathecal chemotherapy, Ommaya reservoirs remain an important alternative for CNS access. Examples of situations where an Ommaya reservoir might be used include patients where spinal anatomy or obesity make lumbar punctures technically challenging, and patients with hydrocephalus, microcephaly or known abnormalities of CSF flow [11] . In addition, for some patients with refractory CNS relapse, use of an Ommaya facilitates frequent reliable delivery of adequate doses of CNS therapy without the need for repeated general anaesthesia.
Although the intrathecal dose of methotrexate is well established and standardised, there is a lack of definitive evidence regarding the optimal dosing of chemotherapy when given as an intraventricular injection via an Ommaya reservoir. We surveyed all UK Paediatric Principal Treatment Centres and found considerable variation in the dose of intraventricular chemotherapy administered to children with ALL, ranging from 100% dosing (i.e. identical to the calculated intrathecal dose) to 20% dosing (Fig. 1 ). There is a clinical need for guidance in this area, as methotrexateinduced neurotoxicity remains a significant side effect of CNS-directed therapy, whilst under-dosing of methotrexate may increase CNS relapse. In this article, we review important safety and efficacy considerations for methotrexate administered via Ommaya reservoir and discuss the clinical and pharmacological differences between intrathecal and intraventricular administration in children with ALL. We conclude by summarising a consensus decision for future dosing of intraventricular methotrexate in ALL.
Clinical Advantages and Limitations of the Ommaya Reservoir
The advantages and limitations of Ommaya reservoirs are discussed in the following subsections (and summarised in Table 1 ).
Safety
Most published studies and case series using [11] . It is therefore challenging to define precisely the safety of Ommaya reservoirs in unselected children with leukaemia. However, Ommaya reservoirs are also used in treatment of paediatric brain tumours. While direct comparison between these two patient populations should be approached with caution, recent case series provide useful data on contemporary short-term complication rates as discussed below.
Bacterial Infection
Peyrl et al. describe in detail their meticulous aseptic approach to administering intraventricular chemotherapy to children with CNS tumours via Ommaya reservoir [12] . Their approach resulted in just one child out of 98 developing an Ommaya-related CNS infection over 20 years. In addition to strict adherence to aseptic technique when delivering intraventricular chemotherapy, they also administered prophylactic antibiotics prior to surgical incision and for 3-5 days post-operatively. Modern neurosurgical technologies were employed to aid catheter placement and MRI studies of the brain and spinal cord were conducted prior to insertion, and the position of the catheter tip was confirmed on CT or MRI scan, post-operatively. This group also avoided using the reservoir for 5 days post-operatively to reduce the risk of retrograde flow of intraventricular therapies through the catheter tract and to promote wound healing around the reservoir. This approach resulted in very low rates of Ommaya-related CNS infection in a large cohort of paediatric cancer patients. It should be noted that this was a case series rather than a comparative study so the contribution of each individual component to the low infection rates is unknown. Another large retrospective analysis of 616 adult and paediatric cancer patients with Ommaya reservoirs report infection rates of 5.5% [13] . Taken together, these reports demonstrate a considerable reduction in the incidence of bacterial infections associated with Ommaya reservoirs compared with earlier reports, which ranged between 15% and 41% [14] [15] [16] . Importantly, the studies agree that increasing numbers of intra-Ommaya injections correlate with an increased risk of infection. However, Peyrl et al. virtually eliminated this risk with a rigorous aseptic protocol for device access [12] .
Misplaced Ommaya Catheters
In older studies, Ommaya catheters were occasionally displaced into the brain parenchyma, often leading to severe complications, such as focal leukoencephalopathy [17] [18] [19] . Modern neurosurgery by comparison benefits from significant improvements in intraoperative neurosurgical technologies and perioperative neuroimaging [20] [21] [22] . These advances should considerably reduce the risk of Ommaya-catheter malposition and allow for accurate assessment of catheter-tip position prior to chemotherapy administration. These improvements optimise safe Ommaya reservoir placement and are likely to reduce significantly the adverse effects of using these implantable devices for administering CNS-directed chemotherapy.
Neurotoxicity
Methotrexate-induced neurotoxicity has been extensively reported in children treated for ALL. It has a variety of clinical presentations from an acute encephalopathy, seizures or a stroke-like syndrome to chronic neurocognitive deficits. Stroke-like syndrome is seen in 1-4% of children treated in modern protocols [23] [24] [25] and presents [24, 26] . One study indicated that children with subclinical leukoencephalopathy are more likely to have long-term neurobehavioural deficits than patients on identical treatment protocols without MRI evidence of leukoencephalopathy [26] . Additional studies have investigated neurocognitive functioning in children treated with contemporary chemotherapy-only treatment regimens [5] . Some studies observe that while most children generally have age-appropriate neurocognition, those treated with higher-intensity protocols are at greater risk of long-term deficits in neurocognitive functioning [28, 29] and executive function [30] . Another large follow-up study supports these observations in a cohort of long-term survivors but did not identify an association with treatment intensity [31] . The relationship between methotrexate drug levels and neurotoxicity is complex. There is evidence that the intensity of methotrexate exposure is associated with neurotoxicity [32] and one study found an association between individual methotrexate exposure levels (area under the curve) and leukoencephalopathy on MRI scanning [24] . On the other hand, there is no clear dose response, patients with stroke-like syndrome can usually be re-exposed to the same dose without recurrence, and it is likely that additional risk factors are present [33] . There is no evidence that intraventricular methotrexate produces higher rates of neurotoxicity than intrathecal methotrexate, although this has not been formally tested in randomised trials. However, the known higher methotrexate concentration in the ventricular CSF when identical doses are given intrathecally or via the intraventricular route (discussed in detail below) raises a theoretical concern of enhanced neurotoxicity and supports the need to consider dose reduction via the intraventricular route.
Systemic Side Effects with Intraventricular Chemotherapy
Owing to slow diffusion of methotrexate across the bloodbrain barrier, CSF can act as a reservoir for systemic drug perfusion, whereby low concentrations of methotrexate continuously enter the circulation from the CSF [34] [35] [36] . Indeed, systemic exposure as measured by red cell accumulation of methotrexate appears greater with intrathecal methotrexate than the same dose given orally [37] and timing of intrathecal methotrexate can influence systemic ALL responses as measured by day 8 peripheral blast count [38] . Furthermore, long exposure to subtherapeutic levels of methotrexate can cause myelosuppression. Leucovorin is sometimes used to alleviate myelosuppression without apparent compromise of methotrexate efficacy [39] . Again, theoretically the high concentrations of methotrexate achieved using Ommaya reservoirs may potentiate these systemic effects if no corresponding dose reduction is used.
Clinical Advantages of Ommaya Reservoir
Ommaya reservoirs are a very efficient method of accessing the CNS, compared with repeated lumbar punctures. Following neurosurgical placement, the procedure of sampling CSF and then administering chemotherapy is straightforward and relatively painless [12, 14] . ). There was one infection in the Ommaya reservoir group, a Staphylococcus epidermidis meningitis, which was successfully treated with intraventricular and intravenous methicillin and which allowed the device to remain functional 4 years later. The authors concluded that, in their experience, intraventricular methotrexate is an efficacious therapy if conducted under expert neurosurgical care and with meticulous aseptic technique.
In 1995, a second retrospective study of 21 adult ALL patients receiving either intraventricular (n = 9) or intrathecal (n = 12) methotrexate for meningeal leukaemia also demonstrated a considerable improvement in CNS leukaemia with intraventricular methotrexate [44] . In patients receiving intraventricular methotrexate, 89% (8/9) had a complete response (CR), defined as complete clinical remission and an absence of malignant cells in CSF from two consecutive weekly CSF samples. None of these eight patients had further CNS relapse and three had no further events, with a median follow-up of 5 years. By comparison, 33% (4/12) of patients receiving intrathecal methotrexate achieved CR, yet two of them developed systemic and CNS relapse. The median survival time after intraventricular treatment was 152 weeks, compared with 14 weeks for intrathecal therapy (p = 0.003). All patients receiving intraventricular methotrexate responded to treatment; the single patient who did not have a CR had a partial response (defined as a 50% reduction in CSF malignant cells with only transient remission). In comparison, 7/12 patients receiving intrathecal methotrexate failed to achieve even a partial response to treatment, which greatly affected cohort median survival times.
It is difficult to draw definitive conclusions from so few comparative studies and small patient numbers. However, given intraventricular methotrexate has been shown to be more effective than intrathecal methotrexate in treating overt meningeal ALL, a multi-centre RCT might be warranted to compare the safety and efficacy of intraventricular versus intrathecal methotrexate for relapsed/refractory CNS leukaemia.
Optimal Dosing of Methotrexate Using Ommaya Reservoirs
Methotrexate is the cornerstone of CNS-directed therapy in childhood ALL. It inhibits dihydrofolate reductase, thereby limiting the availability of reduced folates for purine and pyrimidine synthesis, essential for replication [45] . It is important to consider optimal concentrations of methotrexate to ensure complete ALL clearance from the CNS, while preventing detrimental side effects that can result from overexposure. Based on ex vivo studies using human ALL cells, prolonged exposure to methotrexate concentrations [ 1 lmol/L is more important than brief periods of very high methotrexate levels for eradication of leukaemic cells [46] . An emphasis on prolonged leukaemic exposure to methotrexate to optimise cytotoxicity is supported by an abundance of pre-clinical work, which is discussed in detail by Ettinger et al. [47] . The optimal exposure time is thought to be 48-72 h, as the cell cycle takes approximately 3 days [48, 49] ; however, it might be longer in the CNS due to slower proliferation kinetics in this microenvironment [50, 51] . CSF is formed in the choroid plexus of the cerebral ventricles. It flows through the subarachnoid space in the spinal column and is reabsorbed into plasma, mostly via the arachnoid villi [52] . Several studies have reiterated the observation made by Bleyer et al. in 1973 , that active meningeal leukaemia appears to increase methotrexate halflife within CSF [47, 53, 54] . Grossman et al. demonstrated that neoplastic infiltration of the meninges results in abnormal CSF flow dynamics, such as ventricular outlet obstructions, spinal canal abnormalities and cortical flow delays [55] . Delayed ventricular drainage of methotrexate may sustain high concentrations within the ventricles, potentially leading to neurotoxicity. In one report, children with overt CNS disease (ALL or non-Hodgkin's lymphoma) had significantly higher CSF methotrexate concentrations compared with children treated prophylactically, independent of patient age [47] . A similar study observed normal CSF flow in patients with CNS remission [56] , suggesting that CSF dynamics are crucially affected by the site and extent of meningeal disease. Despite this body of evidence, the clinical implications of these observations and how they might impact on rational dosing of CNS-directed therapy are unclear and modern ALL protocols do not adjust intrathecal doses based on CNS leukemic load.
There has never been a randomised trial of Ommaya versus lumbar puncture delivery of methotrexate. Most studies comparing the two routes were conducted in the 1970s and 1980s and are mainly small case series. Despite this, the following consistent and important observations emerge that help inform decision making on dosing.
Delivery of Methotrexate Via an Ommaya
Reservoir Results in Higher and More Consistent Levels of Methotrexate in the Cerebral Ventricles than Delivery Via Lumbar Puncture
In 1975, Shapiro et al. directly compared Ommaya (intraventricular) and lumbar puncture (intrathecal) administration of methotrexate and showed that intraventricular delivery provided more consistent CSF concentrations when compared with lumbar injection [35] . They administered methotrexate with 131 I-labelled albumin and subsequently scanned patients at 1-, 16-and 40-h post-administration to determine perfusion via the two routes. Methotrexate via Ommaya reservoir was delivered at a dose of 6.25 mg/m 2 , while 6.25-and 12.5-mg/m 2 doses were compared when given intrathecally via lumbar puncture. From this analysis, they observed that despite good CSF flow and manometrics at the time of lumbar puncture, lumbar puncture injections were often misplaced and methotrexate failed to enter the CSF. They further observed that even when lumbar puncture was successful, there was considerable interpatient variability in methotrexate perfusion within the CSF, with up to 100-fold variations in intraventricular concentration when administered via intrathecal lumbar injection. Furthermore, the larger lumbar dose of 12.5 mg/m 2 did not correlate with a higher ventricular concentration of methotrexate. By comparison, ventricular and lumbar CSF methotrexate concentrations were noted to be remarkably consistent when 6.25 mg/m 2 methotrexate was delivered using an Ommaya reservoir. Notably, ventricular and lumbar concentrations of methotrexate were maintained above the therapeutic concentration for at least 48 h when using an Ommaya reservoir. They concluded that use of an Ommaya reservoir produces more consistent concentrations of methotrexate within the CSF. Other studies have also reported that 10% of lumbar punctures are misplaced, resulting in inadvertent injection of drugs into the epidural or subdural spaces [57] . Bleyer et al. showed that following intrathecal delivery of methotrexate the ventricular concentration of methotrexate reaches just 10% of the lumbar concentration [36] . Together, these observations suggest that Ommaya reservoirs result in more reliable delivery plus significantly higher and more sustained methotrexate levels in the cerebral ventricles than the same dose of methotrexate delivered intrathecally. Since the current intrathecal doses are known to be efficacious in preventing CNS relapse, and there is a risk of neurotoxicity with high doses of methotrexate, this evidence supports a reduction of the methotrexate dose when an Ommaya reservoir is used. , maximum dose of 15 mg, twice weekly) [36] . Importantly, the C 9 T protocol maintained methotrexate [ 1 lmol/L in the therapeutic range [46] , whereas the large-bolus regimen peaked shortly after administration, before becoming sub-therapeutic 32 h after delivery [36] . Therefore, the C 9 T protocol demonstrated that smaller doses of methotrexate given intraventricularly at regular dosing intervals could eliminate high peak concentrations of methotrexate within the CNS (thought to be a risk factor for methotrexate-induced neurotoxicity), while maintaining adequate concentrations of methotrexate for the duration of the leukaemic cell cycle to optimise cytotoxicity. Strother et al. [49] noted that studies have consistently failed to demonstrate correlation between higher initial methotrexate doses (12 mg/m 2 ) and peak 24-or 48-h concentrations [35, 36, 47, 48] . They advocate a similar approach as Bleyer et al. [36] , where smaller initial doses are titrated based on CSF sampling to maintain methotrexate concentrations [ 1 lmol/L for at least 72 h, thereby maximising therapeutic potential whilst minimising the risk of neurotoxicity.
Use of Lower
Overall, these studies, whilst not conclusive, support reduced dosing for methotrexate administered via an Ommaya reservoir, and provide no evidence that use of higher doses leads to more sustained therapeutic levels in the CSF.
Other Intrathecal Drugs
No published literature is available on which to base dosing recommendations for the other commonly administered intrathecal drugs for ALL, namely hydrocortisone and cytarabine. Based on the discussion herein, it seems reasonable to extrapolate findings from pharmacokinetic studies of methotrexate to other anti-leukaemic drugs whose dosing was originally established for intrathecal use via lumbar puncture. Thus, we would advocate 50% dosing for all three drugs when triple intrathecal therapy is administered, although we note that this is not evidencebased. This is consistent with current recommendations on the Children's Oncology Group trials in the US (information obtained from clinical trial protocols, unpublished).
Future Recommendations
In the absence of definitive level I evidence to guide clinical decision making, our recommendation is based on the available published evidence. Only centres with expert paediatric neurosurgeons and experience of implanting Ommaya reservoirs should attempt insertion. Adequate MRI neuroimaging of the brain and spinal cord should be carried out shortly before neurosurgical implantation. Adequate staff training, and a meticulous aseptic protocol should be followed to minimise the risk of CNS infection. Centres using Ommaya reservoirs should conduct continuous, thorough clinical audits to identify areas of clinical concern for directed improvement.
Overall, the literature supports dose reductions when using intraventricular methotrexate, compared with intrathecal methotrexate, owing to improved CSF distribution resulting in higher ventricular methotrexate concentrations. While C 9 T dosing regimens with daily lowdose methotrexate [36] may produce optimal methotrexate concentrations, the safety and efficacy of this regimen has not been verified in a large cohort of children. Additionally, repeated Ommaya access is consistently associated with increased rates of infection [12] . As discussed above, in most children a single dose of 50% of the intrathecal dose led to sustained therapeutic concentrations in the CSF for at least 48 h. Monitoring of levels and administration of topup methotrexate at 24 and 48 h could be considered best practice but since similar monitoring and dose modifications are not currently in place for intrathecal methotrexate, its adoption in front-line ALL CNS prophylaxis protocols could be considered a treatment escalation. Therefore, in these situations, we recommend that methotrexate via Ommaya reservoir be administered at 50% of the intrathecal dose, at the same treatment intervals without therapeutic drug monitoring. For patients with relapsed or refractory CNS leukaemia, a fractionated C 9 T approach or use of 50% dosing with monitoring of levels and 'topups' as needed should be considered on a case-by-case basis.
It is clear from the above that further research on this topic is required. A priority for further investigation would be a prospective registry of ALL patients with Ommaya reservoirs capturing indication, dosing regimen, complications and outcome. In addition, given the encouraging historical data suggesting that Ommaya reservoir use results in longer remission [43, 44] and may be preferred by patients [42] , an RCT of Ommaya versus intrathecal methotrexate for relapsed CNS ALL (as part of a systemic multiagent chemotherapy approach) is desirable.
This data was presented and discussed at the UK Childhood Leukaemia Clinicians Network meeting on 23 May 2017. A pragmatic consensus decision was made to recommend administration of 50% doses of all intrathecal chemotherapy to any child requiring intraventricular administration of CNS-directed therapy on front-line ALL protocols, pending any further published evidence to guide rational evidence-based dosing.
